Arcutis Biotherapeutics (NASDAQ:ARQT) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a report released on Thursday, Benzinga reports. The firm currently has a $18.00 price objective on the stock. Separately, Mizuho increased their price target on Arcutis Biotherapeutics from $17.00 to $18.00 and gave the stock a buy […]
More Stories
Prepare to Start Taking Money Out of Your Inherited IRA
By Sandra Block, Kiplinger’s Personal Finance If you’ve postponed taking required distributions from an inherited individual retirement account (IRA), mark...
Israel Says It Has Killed Top Hezbollah Commander
By Dan M. Berger In yet another devastating strike on Hezbollah, an Israeli airstrike on Sept. 20 eliminated its operations...
Sangoma Technologies (NASDAQ:SANG) Issues Earnings Results
Sangoma Technologies (NASDAQ:SANG – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.05) EPS for...
Georgia Election Board Approves Rule Requiring Hand Count of Ballots
By Tom Ozimek The Georgia Election Board has approved a new rule requiring election workers to hand count ballots in...
Cheaper Migraine Drugs Outperform Newer, More Expensive Options: Oxford Study
By Cara Michelle Miller An Oxford study suggests that triptans are the most effective migraine treatment, outperforming newer, pricier options....
SECURITY COUNCIL LIVE: Ambassadors to meet over deepening Lebanon crisis, with region ‘on the brink of catastrophe’
The Security Council is due to hold an emergency meeting in New York on Friday from 3pm, following Israeli strikes...